Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > 266% increase...
View:
Post by wildbird1 on Aug 26, 2024 9:07am

266% increase...

As described in this link...
Five reasons why bowel cancer is becoming more common in under 50s

-There has been a 266% increase in Bowel Cancer rates among adolescents and young adults over the past three decades (the above can be said of almost all cancer).

- With all the new cancer treatments that are available, people with cancer are living longer...but on the other hands the number of people getting cancer is increasing at a faster rate(strange paradox),and patients are getting cancer at a much younger age than before.

It is the FDA job to address this new problem before it become apocalyptic.

OnceTLT-Ruvidar has been approved by the FDA, TLT will push forward with Metformin+Rutherrin to be part the solution for this FDA new big problem, as Metformin+Rutherrin has the potential to easily treat any cancer anywhere in the body.

All the above is one more reason why the FDA has no choice but to give TLT-Ruvidar pre-BTD and BTD approval, before this new problem become apocaliptic.

You have to admit that the future combination of Metformin+Rutherrin is mind-boggling.
Comment by Tarbaby on Aug 26, 2024 11:07am
So far they have only announced that cancer cell lines in a petrie dish have been destroyed by the Rutherrin/Metformin/xray combo. THATS A GREAT START but for major credibility they need to show that same response in live animal studies independantly verified. They should delay their pp until that is done perhaps a month when the share price is much higher..like $1.00...imo.
Comment by Longholder99 on Aug 26, 2024 12:23pm
I'm sure a live animal trial will only take a month to set up, complete, and report on.  Piece of cake.  
Comment by DeathXray33 on Aug 27, 2024 6:49am
Slick-Con-007 has a market cap of 2.53 billion... ------------------------------------------------------------ "Pharma stock Theralase paves way for in-home cancer treatment" ----------- "Pharma stock Theralase Technologies (TSXV:TLT) has found pre-clinical evidence that its lead drug candidate, Rutherrin, is activated by Metformin, a common diabetes drug, without the use of light ...more  
Comment by DeathXray33 on Oct 05, 2024 4:28pm
You definitely want to have Ruvidar Rutherrin for space travel; humans on planet Mars for example.-------------------- "In previous Theralase research, it was demonstrated that Ruvidar combined with transferrin ("Tf") (Rutherrin) was able to utilize the TfR pathway to penetrate a cell; hence, Ruvidar and a virus are in competition for the same TfR receptor. This theoretically ...more  
Comment by Mikee3003 on Aug 26, 2024 3:02pm
"OnceTLT-Ruvidar has been approved by the FDA, TLT will push forward with Metformin+Rutherrin to be part the solution for this FDA new big problem, as Metformin+Rutherrin has the potential to easily treat any cancer anywhere in the body." "All the above is one more reason why the FDA has no choice but to give TLT-Ruvidar pre-BTD and BTD approval, before this new problem become ...more  
Comment by N0taP00p on Aug 26, 2024 3:30pm
@Mikee3003:  I think the Kool-Aid is almost as potent as Ruvidar. 
Comment by Mikee3003 on Aug 26, 2024 4:12pm
Apparently a foreign group is now working on a combo Kool Aid + Metformin treatment. To date there have been incredible petrie dish results for the treatment of pumpastockatitus. 
Comment by DeathXray33 on Aug 26, 2024 5:06pm
"the viral inactivation mediated by TLD-1433-PDT-induced ROS is effective against different families of viruses, not only enveloped but also non-enveloped, via lipid peroxidation and potentially other mechanisms. Immune recognition structures appear to remain intact during this inactivation. This opens potential opportunity to generate a broad spectrum of inactivated virus(es) vaccines with ...more  
Comment by Longholder99 on Aug 26, 2024 5:31pm
Well you know that National Council for Biotechnology Information. Shameless stock pumpers they've always been known to be.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250